Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

the SB-509-401 study was safety, we also observed statistically significant and clinically relevant improvements in a number of quantitative measures of neurological health," said Edward Lanphier, Sangamo's president and CEO. "We believe that SB-509 represents a new therapeutic approach for diabetic neuropathy, designed to directly protect and possibly restore nerve function, in contrast to the current standard of care designed to address the pain associated with this condition. We are encouraged by the data so far and are swiftly moving forward to the next stage of clinical development with our ongoing Phase 2 clinical trials. We expect to have data from our double blind Phase 2 clinical trial (SB-509-601) available in the fourth quarter of this year."

About SB-509

SB-509 is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

About the SB-509 Clinical Program

Sangamo has three ongoing Phase 2 studies in diabetics with sensory/motor neuropathy:

Phase 2 study of SB-509 for mild to moderate DN (SB-509-601)

The clinical trial is a double-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs. The trial is being conducted at multiple sites and is fully enrolled; data is expected to be available in the fourth quarter of 2008.

Approximately 100 subjects have been enrolled into the
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 According to a new ... Product (Natural & Synthetic, Fibrin, Collagen, Gelatin, Cyanoacrylate, Polymeric, ... Global Forecast to 2020", published by MarketsandMarkets, the global ... $2.64 Billion by 2020, growing at a CAGR of ... Browse 119 market T ables and ...
(Date:7/1/2015)... 24, 2015 Research ... of the "2015 Strategies in the Home/Self ... This new 175-page report provides analysis of ... (strips and meters), pregnancy, ovulation, and occult blood. ... requirements, technologies, and competitive profiles. The ...
(Date:7/1/2015)... FT LAUDERDALE, Florida , July 1, 2015 /PRNewswire/ ... manufacturer and marketer of innovative medical devices for the treatment ... it prevailed in a final opposition appeal hearing in the ... 482 - STENT HAVING HELICAL ELEMENTS (,482). The ,482 patent ... and has been upheld as a valid patent in amended ...
Breaking Medicine Technology:Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 3Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 42015 Strategies in the Home/Self Testing Market 2OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2
... Inc., (OTC Bulletin Board: NWCI ) a ... the second quarter ended June 30, 2010. More details ... 10-Q, filed with the Securities and Exchange Commission. ... made tremendous progress in commercializing our initial solution, QTinno™," ...
... Colo., Aug. 13 Mesa Laboratories, Inc. (Nasdaq: ... Directors has declared a regular quarterly cash dividend of ... September 15, 2010 to shareholders of record at the ... Mesa Laboratories develops, acquires, manufactures and markets electronic instruments ...
Cached Medicine Technology:NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 2NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 3NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 4NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 5NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 6NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 7NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 8NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 9NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress 10
(Date:7/1/2015)... York, New York (PRWEB) , ... July 01, ... ... injury lawsuit filed against the manufacturers of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted ... U.S. District Court, Southern District of West Virginia on June 26th, the Court ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... and services, today announced that its fifth annual Smile for a Lifetime Foundation ... for the non-profit organization. In addition to supporting S4L in its mission to ...
(Date:7/1/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich ... for March 6th - 8th, the 2016 meeting will be held at the Westin ... of nasal surgery through the most modern advancements and updates in rhinoplasty and ...
(Date:7/1/2015)... Tenn. (PRWEB) , ... July 01, 2015 , ... The ... held rain or shine Saturday, July 11, 2015, at 6 p.m. in Pugh Bourne ... free and includes pony rides, a petting zoo, an Elvis impersonator, a silent auction ...
(Date:7/1/2015)... ... July 01, 2015 , ... Trevor L. Williams, DMD holds a Bachelor ... at USF earning a Master’s degree in Microbiology. He graduated from the University of ... Dental Association, the Florida Dental Association and the Academy of General Dentistry. Dr. Williams ...
Breaking Medicine News(10 mins):Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2
... Jiffy Lube® service centers in San Luis Obispo and ... the Spokane and Tri-Cities are of Washington and the ... year of the company,s Maintenance Partners for Life campaign ... For Women movement. Heart disease is the nation,s number ...
... Kan., Jan. 29 Because pets deserve a great ... Hill,s(R) Prescription Diet(R) and Hill,s(R) Science Diet(R) brand pet ... Care, Too(TM) campaign. This campaign provides veterinary health care ... of scheduling regular, professional oral health exams and establishing ...
... for 2009DALLAS, Jan. 29 For the second time in four ... Texas - has been named one of the state,s top employers ... to Work for in Texas." Medical City is the only ... only hospital in the state to rank in the top ten. ...
... Much of the work involves older homes, but lead paint ... -- Home renovations, repairs and painting can lead to elevated ... lead-poisoning risk among children, according to a new U.S. study. ... for lead poisoning than white children. Much of those disparities ...
... two important protein kinase signaling pathways that are associated ... the January 30th issue of the journal Molecular ... types of cancer. , The protein kinase LKB1 is ... couples energy metabolism with cell growth, proliferation and survival. ...
... January 29, 2009 (BRONX, NY) Men who develop ... tumor if they carry a so-called breast cancer gene mutation, ... University report in today,s issue of Clinical Cancer Research ... their physicians in choosing treatment options. , The study, ...
Cached Medicine News:Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 2Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 3Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 4Health News:Pet Dental Health Campaign Urges Pet Owners Not to Brush off Dental Homecare 2Health News:Medical City Hospital Named by Texas Monthly as One of the Top Ten Best Companies to Work for in Texas 2Health News:Home Renovations by Affluent Families Can Unleash Lead Threat 2Health News:Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1 2Health News:Gene mutations increase risk for aggressive prostate cancer 2Health News:Gene mutations increase risk for aggressive prostate cancer 3
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
... used for in or out-of-office screenings and for ... from 20/15 to 20/200, two rows of spatial ... driver's scene. , ,The test is very useful ... acuity score, a functional acuity score and a ...
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
Medicine Products: